Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818297 | 0.89 | ALDH1A1 (0.40) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL12457822 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL13221517 | 0.86 | ALDH1A1 (0.42) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL29382448 | 0.84 | ALDH1A1 (0.38) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL2179698 | 0.83 | ALDH1A1 (0.40) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL109045 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL22064175 | 0.78 | KMT2A (0.46) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL22203030 | 0.77 | MEN1 (0.46) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL20026779 | 0.77 | KMT2A (0.41) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL21126518 | 0.77 | KMT2A (0.45) | ALDH1A1HPGDMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563509-B2 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates | IMMUNOGEN INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8163888-B2 | Potent, durable cytotoxic agents; tissue targeted therapy; tumors, autoimmune diseases, graft versus host disease, viral and parasite infections | IMMUNOGEN, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110281856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7989598-B2 | Antibodies; tissue-targeted therapy; for treatment of tumors, autoimmune diseases, graft rejections, graft versus host disease, viral infections, parasite infections | IMMUNOGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080171856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080145374-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN, INC. (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | FOLH1, DNPEP, SELPLG | ALDH1A1 1264/4885HPGD 1119/4885MEN1 1568/4885 |
| US-20080171856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | FOLH1, DNPEP, SELPLG | ALDH1A1 1264/4885HPGD 1119/4885MEN1 1568/4885 |
| US-20080145374-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | FOLH1, DNPEP, SELPLG | ALDH1A1 1264/4885HPGD 1119/4885MEN1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.